| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 44 | 2022 | 2161 | 5.940 |
Why?
|
| Brain Ischemia | 21 | 2020 | 665 | 3.550 |
Why?
|
| Periodontal Diseases | 7 | 2022 | 54 | 3.490 |
Why?
|
| Ischemic Attack, Transient | 10 | 2020 | 167 | 3.380 |
Why?
|
| Atherosclerosis | 10 | 2022 | 204 | 2.630 |
Why?
|
| Atrial Fibrillation | 6 | 2021 | 248 | 2.320 |
Why?
|
| Migraine with Aura | 4 | 2019 | 6 | 2.150 |
Why?
|
| Carotid Artery, Internal, Dissection | 2 | 2021 | 9 | 1.580 |
Why?
|
| Vertebral Artery Dissection | 2 | 2021 | 8 | 1.580 |
Why?
|
| Aortic Diseases | 8 | 2017 | 113 | 1.570 |
Why?
|
| Aorta, Thoracic | 10 | 2019 | 211 | 1.560 |
Why?
|
| HIV Infections | 4 | 2022 | 775 | 1.530 |
Why?
|
| Risk Factors | 24 | 2021 | 5719 | 1.260 |
Why?
|
| Emergency Medical Services | 2 | 2020 | 225 | 1.210 |
Why?
|
| Anticoagulants | 4 | 2020 | 356 | 1.120 |
Why?
|
| Cerebrovascular Circulation | 4 | 2022 | 296 | 0.900 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2014 | 296 | 0.890 |
Why?
|
| Migraine Disorders | 2 | 2019 | 66 | 0.810 |
Why?
|
| Humans | 60 | 2022 | 68525 | 0.780 |
Why?
|
| Middle Aged | 36 | 2021 | 21119 | 0.780 |
Why?
|
| Basilar Artery | 1 | 2020 | 38 | 0.750 |
Why?
|
| Aged | 32 | 2022 | 14842 | 0.740 |
Why?
|
| Incidence | 9 | 2021 | 1582 | 0.730 |
Why?
|
| Female | 41 | 2021 | 38015 | 0.720 |
Why?
|
| Ambulances | 1 | 2019 | 27 | 0.720 |
Why?
|
| White Matter | 1 | 2022 | 174 | 0.710 |
Why?
|
| Male | 37 | 2021 | 37281 | 0.700 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 117 | 0.700 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 373 | 0.680 |
Why?
|
| Prospective Studies | 11 | 2021 | 3702 | 0.660 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 176 | 0.660 |
Why?
|
| Epilepsy | 2 | 2019 | 336 | 0.640 |
Why?
|
| Dental Care | 1 | 2018 | 34 | 0.630 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 3256 | 0.610 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 125 | 0.560 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2016 | 61 | 0.550 |
Why?
|
| Registries | 3 | 2020 | 730 | 0.550 |
Why?
|
| Fibrinolytic Agents | 3 | 2012 | 377 | 0.540 |
Why?
|
| Risk Assessment | 2 | 2021 | 2004 | 0.520 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 467 | 0.520 |
Why?
|
| Aphasia | 3 | 2021 | 119 | 0.470 |
Why?
|
| Fear | 1 | 2014 | 239 | 0.460 |
Why?
|
| Longitudinal Studies | 5 | 2020 | 1054 | 0.460 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 415 | 0.450 |
Why?
|
| Arteriosclerosis | 2 | 2003 | 137 | 0.430 |
Why?
|
| Cohort Studies | 7 | 2019 | 2356 | 0.430 |
Why?
|
| Stroke Rehabilitation | 2 | 2021 | 334 | 0.410 |
Why?
|
| Tooth Loss | 2 | 2022 | 7 | 0.400 |
Why?
|
| Treatment Outcome | 13 | 2021 | 7028 | 0.400 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 442 | 0.400 |
Why?
|
| Middle Cerebral Artery | 3 | 2004 | 57 | 0.370 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 503 | 0.360 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2019 | 100 | 0.350 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 50 | 0.350 |
Why?
|
| Adult | 12 | 2022 | 21375 | 0.350 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2009 | 105 | 0.310 |
Why?
|
| HIV | 2 | 2021 | 53 | 0.310 |
Why?
|
| Inflammation | 3 | 2017 | 1030 | 0.290 |
Why?
|
| Transcranial Direct Current Stimulation | 2 | 2018 | 111 | 0.290 |
Why?
|
| Blood Pressure | 2 | 2022 | 1447 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2021 | 7264 | 0.260 |
Why?
|
| Thrombolytic Therapy | 2 | 2004 | 233 | 0.260 |
Why?
|
| Recurrence | 4 | 2017 | 948 | 0.260 |
Why?
|
| South Carolina | 3 | 2021 | 2750 | 0.260 |
Why?
|
| Aspirin | 2 | 2019 | 295 | 0.250 |
Why?
|
| Cardiology | 3 | 2010 | 140 | 0.250 |
Why?
|
| United States | 7 | 2021 | 7335 | 0.250 |
Why?
|
| Homocysteine | 3 | 2013 | 26 | 0.250 |
Why?
|
| Time Factors | 5 | 2021 | 4655 | 0.240 |
Why?
|
| Coronary Thrombosis | 1 | 2003 | 45 | 0.240 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 134 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 536 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2010 | 2323 | 0.230 |
Why?
|
| Angioplasty | 1 | 2004 | 118 | 0.230 |
Why?
|
| Postmenopause | 2 | 2013 | 92 | 0.220 |
Why?
|
| Hyperhomocysteinemia | 1 | 2002 | 15 | 0.210 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2798 | 0.210 |
Why?
|
| Prevalence | 4 | 2019 | 1609 | 0.210 |
Why?
|
| Secondary Prevention | 2 | 2021 | 291 | 0.210 |
Why?
|
| Acute Disease | 5 | 2009 | 658 | 0.210 |
Why?
|
| Cerebral Angiography | 4 | 2009 | 151 | 0.210 |
Why?
|
| Dissection | 1 | 2021 | 29 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2017 | 447 | 0.200 |
Why?
|
| Safety-net Providers | 1 | 2021 | 20 | 0.200 |
Why?
|
| Myocardial Infarction | 2 | 2017 | 807 | 0.200 |
Why?
|
| Homeostasis | 1 | 2022 | 291 | 0.190 |
Why?
|
| Arteries | 1 | 2021 | 108 | 0.190 |
Why?
|
| Biomarkers | 2 | 2021 | 1593 | 0.190 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 36 | 0.190 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 106 | 0.190 |
Why?
|
| Disease Progression | 4 | 2016 | 1037 | 0.190 |
Why?
|
| Periodontitis | 1 | 2020 | 47 | 0.180 |
Why?
|
| Oxygen | 1 | 2021 | 386 | 0.180 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 25 | 0.180 |
Why?
|
| Rivaroxaban | 1 | 2019 | 26 | 0.180 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 791 | 0.180 |
Why?
|
| Migraine without Aura | 1 | 2019 | 1 | 0.170 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 567 | 0.170 |
Why?
|
| Thoracic Surgery | 2 | 2010 | 72 | 0.170 |
Why?
|
| Survivors | 1 | 2021 | 254 | 0.170 |
Why?
|
| Speech Therapy | 1 | 2018 | 19 | 0.170 |
Why?
|
| Vascular Surgical Procedures | 2 | 2010 | 168 | 0.170 |
Why?
|
| Data Mining | 1 | 2019 | 45 | 0.170 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 201 | 0.170 |
Why?
|
| Self Care | 1 | 2021 | 252 | 0.170 |
Why?
|
| Genotype | 2 | 2018 | 785 | 0.160 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2010 | 134 | 0.160 |
Why?
|
| Disability Evaluation | 1 | 2020 | 298 | 0.160 |
Why?
|
| Coronary Disease | 1 | 2020 | 358 | 0.160 |
Why?
|
| Inpatients | 1 | 2019 | 208 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2020 | 294 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 142 | 0.160 |
Why?
|
| Double-Blind Method | 5 | 2021 | 1737 | 0.160 |
Why?
|
| Headache Disorders, Secondary | 1 | 2017 | 1 | 0.160 |
Why?
|
| Predictive Value of Tests | 5 | 2010 | 1465 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2019 | 880 | 0.150 |
Why?
|
| Multipotent Stem Cells | 1 | 2017 | 6 | 0.150 |
Why?
|
| Adult Stem Cells | 1 | 2017 | 13 | 0.150 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 124 | 0.150 |
Why?
|
| Injections, Intra-Arterial | 2 | 2009 | 30 | 0.150 |
Why?
|
| Stents | 1 | 2021 | 657 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1548 | 0.140 |
Why?
|
| Glafenine | 1 | 2016 | 1 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4843 | 0.140 |
Why?
|
| Spin Labels | 1 | 2016 | 27 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 149 | 0.140 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2009 | 21 | 0.140 |
Why?
|
| Injections, Intravenous | 2 | 2009 | 215 | 0.140 |
Why?
|
| Hypertension | 2 | 2021 | 1531 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 124 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 848 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 1851 | 0.140 |
Why?
|
| Smoke | 1 | 2016 | 46 | 0.140 |
Why?
|
| Connectome | 1 | 2017 | 91 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 53 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2077 | 0.140 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 76 | 0.140 |
Why?
|
| Th1 Cells | 1 | 2016 | 101 | 0.130 |
Why?
|
| Nerve Net | 1 | 2017 | 180 | 0.130 |
Why?
|
| Comorbidity | 3 | 2019 | 1425 | 0.130 |
Why?
|
| Fractures, Bone | 1 | 2016 | 132 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 785 | 0.120 |
Why?
|
| Multiple Sclerosis | 1 | 2016 | 132 | 0.120 |
Why?
|
| Minisatellite Repeats | 1 | 2014 | 16 | 0.120 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2014 | 17 | 0.120 |
Why?
|
| Brain | 2 | 2022 | 2175 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2016 | 241 | 0.120 |
Why?
|
| Catheters, Indwelling | 1 | 2014 | 72 | 0.120 |
Why?
|
| Hospitalization | 1 | 2019 | 977 | 0.120 |
Why?
|
| Dental Plaque | 1 | 2013 | 14 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1293 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 361 | 0.110 |
Why?
|
| Telemedicine | 1 | 2021 | 699 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2014 | 328 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2013 | 222 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 689 | 0.110 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2012 | 8 | 0.110 |
Why?
|
| Prognosis | 1 | 2017 | 2093 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 714 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 73 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 186 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 2013 | 295 | 0.100 |
Why?
|
| Hospitals | 1 | 2013 | 265 | 0.100 |
Why?
|
| Patient Selection | 1 | 2014 | 592 | 0.100 |
Why?
|
| Language Therapy | 2 | 2021 | 9 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2013 | 267 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 2222 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 627 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 371 | 0.090 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 12 | 0.090 |
Why?
|
| Young Adult | 2 | 2021 | 5708 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2007 | 349 | 0.090 |
Why?
|
| Cytokines | 1 | 2013 | 866 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 166 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2009 | 83 | 0.080 |
Why?
|
| Smoking | 1 | 2016 | 1449 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2010 | 403 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2007 | 94 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 929 | 0.080 |
Why?
|
| Age Factors | 1 | 2012 | 1860 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2009 | 652 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 133 | 0.070 |
Why?
|
| Critical Care | 1 | 2009 | 263 | 0.070 |
Why?
|
| Adolescent | 2 | 2021 | 8903 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2007 | 453 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 239 | 0.060 |
Why?
|
| Retreatment | 1 | 2004 | 59 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 498 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2004 | 216 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 700 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2002 | 25 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2021 | 20 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 938 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2014 | 207 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2002 | 82 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 58 | 0.050 |
Why?
|
| Demography | 1 | 2002 | 279 | 0.050 |
Why?
|
| Alleles | 2 | 2014 | 386 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 84 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2022 | 122 | 0.050 |
Why?
|
| Smartphone | 1 | 2021 | 69 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2022 | 190 | 0.050 |
Why?
|
| Logistic Models | 1 | 2004 | 1419 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2010 | 181 | 0.050 |
Why?
|
| PubMed | 1 | 2019 | 21 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2021 | 138 | 0.040 |
Why?
|
| Aphasia, Broca | 1 | 2018 | 11 | 0.040 |
Why?
|
| Neurology | 1 | 2019 | 43 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 126 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 255 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 188 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 195 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 248 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2018 | 125 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2018 | 229 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2021 | 335 | 0.040 |
Why?
|
| Rest | 1 | 2017 | 78 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 213 | 0.040 |
Why?
|
| Executive Function | 1 | 2017 | 106 | 0.040 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2016 | 7 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2016 | 29 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2016 | 35 | 0.030 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2016 | 19 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 218 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 94 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 766 | 0.030 |
Why?
|
| Weight Gain | 1 | 2016 | 135 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 226 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 266 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 241 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 631 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 447 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 729 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 1015 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 103 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2017 | 506 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 1329 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 30 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 242 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1034 | 0.030 |
Why?
|
| Health Surveys | 1 | 2013 | 488 | 0.020 |
Why?
|
| Women's Health | 1 | 2012 | 148 | 0.020 |
Why?
|
| Aortography | 1 | 2010 | 72 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 301 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 710 | 0.020 |
Why?
|
| Echocardiography | 1 | 2010 | 515 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 7 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2009 | 718 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 1615 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2002 | 63 | 0.010 |
Why?
|